Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.
Hepatocellular Carcinoma|Adjuvant Therapy
DRUG: Donafenib
One year recurrence-free survival (RFS) rate, The proportion from randomization to 1 year without recurrence., 1 year
Recurrence-Free Survival (RFS ), The time from randomization to disease recurrence, or death from any cause (whichever occurs first)., 6 years|Recurrence-Free Survival rate (RFS rate), The proportion from randomization to 2 years, 3 years or 5 years without recurrence., 5 years|Overall Survival (OS), The time from randomization to death from any cause., 6 years
This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.